LONDON – A 10-year analysis of how pharma is working to improve access to medicines in the developing world shows the industry has moved beyond paying lip service and is implementing policies that provide more and better drugs in poorer countries. Read More
HONG KONG – Pharmaceutical manufacturer Huons Co. Ltd. and biopharmaceutical research and development venture Genexine Inc. inked a memorandum of understanding for a deal, under which they will combine Genexine's biobetters and rare disease pipeline with Huons' existing global commercial network. Read More
HONG KONG – The Korea Cancer Biomarker Consortium (KCBC), a research group of 13 university hospitals in South Korea, and South Korean biotech Cbsbioscience Inc. inked a deal with medical research institutes in Italy and Japan to develop biomarkers aimed at improving the efficiency of cancer drugs. Read More
Rather than develop vonoprazan in the U.S., Europe and Canada on its own, Takeda Pharmaceutical Co. Ltd. decided to spin the drug out into a new company, Phathom Pharmaceuticals Inc., with the help of venture capitalists at Frazier Healthcare Partners. Read More
TEL AVIV, Israel – An awakening is underway in the biotech field to develop new products from cannabis, with efforts based on strong science and supported by clinical trials and rigorous research, particularly into the many potential uses of cannabinoids. Read More
Kazia Therapeutics Ltd., of Sydney, entered a collaboration with the Alliance for Clinical Trials in Oncology Foundation, a U.S.-based cancer research network sponsored by the National Cancer Institute. Alliance will launch a multicenter phase II study to investigate the potential use of Kazia's GDC-0084, alongside several other targeted cancer therapies, in the treatment of brain metastases. Read More
Sanbio Group, of Tokyo, appointed Bijan Nejadnik chief medical officer in charge of development and regulatory affairs. Nejadnik held key roles at Johnson & Johnson, as well as pioneering clinical programs at Jazz Pharmaceuticals plc, Galena Biopharma Inc. and Eureka Therapeutics Inc. Read More
